Company News: Bristol-Myers Squibb, Mead Johnson and Covidien

Share this article:
Bristol-Myers Squibb said it will split off nutritional business Mead Johnson through a share exchange offer to its stockholders. BMS currently has an 83.1% stake in Mead Johnson—equivalent to 170 million shares. The company said the cashless transaction gives it more room to fund future growth, particularly around biotech drugs.
 
Covidien, which owns marketing rights to experimental pain drug Exalgo, said the drug's developer is in discussions with FDA staff regarding a pending application. According to Covidien, the agency told Exalgo developer Neuromed that its NDA was not sufficient to form the basis for approval. The FDA will complete its review of the opioid drug on November 22. Covidien, whose Mallinckrodt unit obtained the US commercial rights to Exalgo in June, is working with Neuromed to determine next steps.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.